№ files_lp_3_process_9_33336
File format: docx
Character count: 3559
File size: 138 KB
Year:
2026
Region / City:
Kent, Aylesford
Topic:
Safety and Hazard Assessment
Document Type:
Risk Assessment
Organization / Institution:
Guest Medical Limited
Author:
Pete Reynolds
Target Audience:
Employees, Sub-contractors, Public
Validity Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Control Measures:
Use in well ventilated areas
Personal Protective Equipment:
Dust mask, Visor, Goggles, Gloves, Overalls, Footwear
Health Surveillance Required:
Yes
Exposure Adequately Controlled:
Yes
Risk Rating:
High
Context:
Risk assessment of HAZ-TAB Granules, including safety and health risks, exposure controls, and required personal protective equipment for handling hazardous substances in the workplace.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
ISO Common Name:
Ametryn
Chemical Name:
4-N-ethyl-6-methylsulfanyl-2-N-propan-2-yl-1,3,5-triazine-diamine
Empirical Formula:
C9H17N5S
Relative Molecular Mass:
227.33
Boiling Point:
about 248°C (decomposition)
CAS Number:
834-12-8
CIPAC Code:
133
Method Status:
Provisional CIPAC method 2020
Based on:
Method supplied by Syngenta Crop Protection, USA
Document Type:
Analytical method
Analyte:
Ametryn
Formulations Covered:
Technical material (TC), Water Dispersible Granules (WG), Suspension Concentrates (SC)
Analytical Technique:
Capillary gas chromatography with flame ionization detection
Identity Tests:
Infrared spectrometry; Gas-liquid chromatography
Sampling Requirements:
Minimum 250 g (TC, WG) or 250 ml (SC)
Repeatability (TC):
10–13 g/kg at 968–972 g/kg
Reproducibility (TC):
19–20 g/kg at 968–972 g/kg
Repeatability (WG):
14 g/kg at 795 g/kg
Reproducibility (WG):
34 g/kg at 795 g/kg
Repeatability (SC):
7.7–10 g/kg at 435–447 g/kg
Reproducibility (SC):
19–20 g/kg at 435–447 g/kg
Year:
2025
Region / City:
Australia
Topic:
Cystic fibrosis treatment
Document Type:
Submission for listing in Section 100, Highly Specialised Drugs Program
Organization:
Vertex Pharmaceuticals Pty Ltd
Author:
Vertex Pharmaceuticals Pty Ltd
Target Audience:
Healthcare professionals, Medical practitioners
Effective Date:
February 6, 2025
Date of Last Consideration:
November 2023
Treatment Phase:
Initial treatment, Continuing treatment
Indication:
Cystic fibrosis
Population:
Patients aged 1 to 4 months with specific mutations in CFTR gene
Clinical Criteria:
Must be assessed through a cystic fibrosis clinic/center, G551D mutation or other gating mutations in CFTR gene
Prescription Type:
Authority Required
Date of Submission:
5 October 2025
Modification Date:
Not specified
Status:
Registered
Listing Request Basis:
Clinical need, equity
Background:
Ivacaftor approved for treatment of CF
Context Description:
A submission for listing a new strength of ivacaftor (13.4 mg granules) for cystic fibrosis patients aged 1 to 4 months with specific CFTR gene mutations, requesting inclusion in the Highly Specialised Drugs Program.
Medicinal Product:
Hydrocortisone granules in capsules 0.5 mg, 1 mg, 2 mg, 5 mg (Alkindi®)
Sponsor:
Chiesi Australia
Regulatory Status:
Registered in the ARTG by the TGA on 18 August 2020
Orphan Drug Status:
Granted by the TGA
Submission Type:
Category 3 submission
Requested Listing:
Authority Required (STREAMLINED), General Schedule (Code GE)
Indication:
Replacement therapy of adrenal insufficiency
Population Criteria:
Patients diagnosed and initiated on treatment at 6 years of age or less; or patients 6 years of age or older with difficulty swallowing hydrocortisone tablets resulting in poor treatment compliance
Comparator:
Hydrocortisone 4 mg and 20 mg tablets (Hydrocortisone Mylan 4®, Hysone 4®, Hydrocortisone Mylan 20®, Hysone 20®)
Legislative Framework:
Section 101(3B) of the National Health Act 1953
Clinical Studies:
Infacort 001; Infacort 003; Infacort 004
Hearing:
No sponsor hearing conducted
Consumer Input:
Comments received from individuals, health care professionals and organisations via the PBS website
Economic Analysis:
Not presented
Authors:
Tony Malmqvist; Karen Anthony; Jean-Marc Gallo
Affiliation:
Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry, London, United Kingdom
Corresponding Author:
Jean-Marc Gallo
Institutional Address:
King’s College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, United Kingdom
Type of Document:
Scientific research article
Field of Study:
Neuroscience; Molecular and Cellular Biology
Research Subject:
Localization and translation of tau mRNA in rat cortical neurons
Biological Material:
Primary rat cortical neurons
Key Methods:
Fluorescence in situ hybridization (FISH); RNA staining; immunocytochemistry
Key Molecules:
Tau mRNA; eukaryotic elongation factor 1A (eEF1A); neurofilament heavy subunit (NF-H)
Geographical Context:
London, United Kingdom
Institutional Context:
King’s College London, Institute of Psychiatry
Language:
English
Year:
2026
Note:
Region / City
Subject:
Health and safety assessment for hazardous substances in the workplace
Document Type:
Risk Assessment
Organization / Institution:
STFC
Target Audience:
Employees and health & safety staff
Year:
2023
Region / City:
UK
Subject:
Risk Assessment
Document Type:
Risk Assessment Form
Institution:
Faculty of Environment, University of Leeds
Author:
Caroline Peacock, Andy Connelly
Target Audience:
Laboratory personnel, researchers
Validity Period:
Not specified
Approval Date:
Not specified
Revision Date:
Not specified
Year:
Not specified
Region / City:
Not specified
Theme:
Hazardous substances and safety
Document type:
Risk assessment form
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Staff, Postgraduates, Undergraduates, Contractors, Visitors
Effective period:
Not specified
Approval date:
Not specified
Revision date:
Not specified
Note:
Year
Year:
2026
Region / City:
Stockport, United Kingdom
Subject:
Health and Safety
Document Type:
Guidance Notes
Organization:
Stockport Metropolitan Borough Council
Author:
Health, Safety and Wellbeing Team
Target Audience:
School staff and contractors
Scope:
Management and control of hazardous substances in schools
Hazard Types Covered:
Chemicals, products containing chemicals, fumes, dusts, vapours, mists, nanotechnology, gases, biological agents
Exclusions:
Lead, Asbestos, Radioactive substances
Reference Documents:
SMBC CoSHH Management Policy, HSE CoSHH Guidance
Year:
Not specified
Region / City:
United Kingdom
Subject:
Hazardous substances management
Document Type:
Guidance / Regulatory reference
Authority / Institution:
Health and Safety Executive (HSE)
Keywords:
COSHH, hazardous, dangerous, explosive, flammable, corrosive, toxic
Target Audience:
Employers, safety officers, regulatory personnel
Legislation Period:
Current
Date of Issue:
Not specified
Date of Amendments:
Not specified
Year:
2025
Region / City:
Buxton, Derbyshire
Topic:
Health and Safety Risk Assessment
Document Type:
Assessment Sheet
Organization / Institution:
Selden Research Limited
Author:
Daniel Looney
Target Audience:
Employees, Contractors, Health and Safety Personnel
Period of Validity:
Until next assessment
Approval Date:
03.12.2025
Modification Date:
N/A
Year:
2026
Region / City:
Not specified
Document Type:
Safety Assessment Record
Organization:
Dental Practice
Responsible Person:
COSHH Lead
Assessment Period:
Not specified
Document Version:
v1.0
Last Review Date:
Not completed
Next Review Due:
Not specified
Intended Users:
Dental staff handling hazardous substances
Year:
2025
Region / City:
Enfield, UK
Topic:
Health and safety assessment
Document Type:
Risk Assessment
Organization:
Chela Ltd
Author:
Daniel Looney
Target Audience:
Employees, Contractors
Effective Period:
Until further notice
Approval Date:
04.02.2025
Modification Date:
N/A
Year:
Not specified
Region / City:
Not specified
Subject:
Occupational Health and Safety
Document Type:
Toolbox Talk
Organization:
HSE (Health, Safety, Environment)
Author:
HSE Advisor
Reviewed by:
HSE Manager
Document ID:
TBT-001
Revision Number:
0
Effective Date:
DD.MM.YYYY
Sections Revised:
N/A
Training Required:
Yes
Personal Protective Equipment Required:
Yes
Emergency Procedures Included:
Yes
Target Audience:
Personnel working with hazardous substances